(Press-News.org) PLYMOUTH MEETING, PA [April 16, 2024] — New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer. Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%. When pancreatic neoplasms are detected early enough for treatment with surgical resection, the survival rate climbs to better than 80%, but unfortunately the vast majority of patients are diagnosed with advanced-stage disease. The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease. Of 1,759 participants sorted into the highest-risk cohort, nearly 80% completed baseline imaging through PRECEDE.
“Individuals who are concerned they are at risk for pancreatic cancer can participate in PRECEDE and obtain an assessment from a PRECEDE site,” explained co-lead author George Zogopoulos, MD, PhD of the Research Institute of the McGill University Health Centre and the Rosalind and Morris Goodman Cancer Institute at McGill University in Canada. “If the individual is assessed to be at increased risk for pancreatic cancer, they will have the opportunity to undergo clinical surveillance for pancreatic cancer according to the clinical surveillance services available in their area. Based on our findings, we recommend sorting individuals at high risk for pancreatic cancer into three groups based on family history of pancreatic cancer, the existence of a potentially cancer-causing genetic mutation, or both.”
The researchers found a higher incidence of pancreatic cysts in people sorted into the high-risk sub-group based only on family history compared to those with a known genetic predisposition for pancreatic cancer but no family history of it.
“The presence of cysts may identify individuals that are at increased risk of developing pancreatic cancer over time because of cyst changes or because the presence of cysts signals that the pancreas has an intrinsic aberration making it more susceptible to cyst progression or other precancerous growths,” said senior author Diane M. Simeone, MD, UC San Diego Moores Cancer Center (New York University Langone Health at the time of study). “Longer follow-up time is needed to determine if familial pancreatic cancer signifies a higher risk for developing pancreatic cancer compared to pathogenic germline variant (PGV) status in a pancreatic cancer predisposition gene.”
“This research highlights that—although barriers have prevented the wide-spread implementation of pancreatic cancer screening programs for high-risk individuals—a multicenter international consortium and longitudinal study is feasible; early imaging findings from this study show the need for further pancreatic cancer early detection research,” commented Cassadie Moravek, Senior Director of Clinical Trial Portfolio and Program Management, Pancreatic Cancer Action Network (PanCAN).
Moravek, who is a patient advocate on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Pancreatic Adenocarcinoma, continued: “Low overall survival rates in pancreatic cancer are often attributed to the majority of patients having advanced-stage disease at diagnosis, underscoring the need for improved screening for pancreatic cancer to detect the disease at earlier stages. While the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic recommend pancreatic cancer screening in select individuals based on known pathogenic germline variants and family history, this study showed that further research in this area is needed to better tailor surveillance to distinct subclassifications of high-risk individuals. The study also identifies a high prevalence of pancreatic cysts in high-risk individuals that do not fully overlap with risks based on known pathologic genetic alterations. I look forward to further research in this area, building upon the infrastructure support of this international consortium, to improve access to pancreatic cancer screening for high-risk individuals, and in turn, advance early detection of pancreatic cancer and improve clinical outcomes.”
The PRECEDE sites are located throughout North America and Europe. Several NCCN Member Institutions are involved, including Abramson Cancer Center at the University of Pennsylvania, Dana-Farber Cancer Institute, Fred & Pamela Buffett Cancer Center, Fred Hutchinson Cancer Center, Huntsman Cancer Institute at the University of Utah, Mass General Cancer Center, Mayo Clinic Comprehensive Cancer Center, UC San Diego Moores Cancer Center, and Yale Cancer Center/Smilow Cancer Hospital.
To read the entire study, visit JNCCN.org. Complimentary access to “The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals” is available until July 10, 2024.
# # #
About JNCCN—Journal of the National Comprehensive Cancer Network
More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside/BroadcastMed. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit NCCN.org/jnccn/subscribe. Follow JNCCN on Twitter @JNCCN.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
END
ITHACA, N.Y. – Cornell University researchers are working to eliminate the rotten egg aroma that sometimes accompanies canned wine by ever-so-slightly altering the product’s formulation and packaging, which is also prone to corrosion.
In recent research, the team – led by Gavin Sacks and Julie Goddard, both professors of food science – found that the choice of the ultrathin plastic coating inside aluminum cans can go a long way towards improving the aroma of the beverage and the lifespan of its container.
The collaboration began ...
Building on the anti-tumor potential of Polθ inhibition in BRCA-deficient cancers, researchers at Insilico Medicine discovered a new class of orally bioavailable Polθ inhibitors designed using generative AI.
For molecular generation, they used both ligand-based drug design (LBDD) and structure-based drug design (SBDD) strategies within the Chemistry42 generative chemistry engine.
The new inhibitors demonstrated strong potency and promising druglike properties, highlighting AI’s potential in medicinal chemistry for precise molecular modifications.
A crucial player in genomic integrity maintenance, DNA Polymerase Theta (Polθ) provides a potential synthetic lethal ...
Robots are increasingly being used in industry, and in future they will need to adapt to unforeseen events and changes in their environment much more than today, including when they work with humans.
A new international research project is addressing this issue using artificial intelligence. The project is being funded by Horizon Europe, the EU framework programme for research and innovation, with a grant of DKK 56 million (EUR 7.5 million) and is called RoboSapiens (Robotic Safe Adaptation In Unprecedented Situations).
The RoboSapiens project will reduce ...
(Santa Barbara, Calif.) — As artificial intelligence continues to boom, scaling algorithms to ever-increasing data sets also becomes a bigger hurdle. Such is the case in the domain of natural language processing (NLP), or, the effort to get machines to understand and communicate with human language (think: ChatGPT, search engines and other text-based modalities).
“A key challenge in this domain is the tradeoff between scalability and accuracy,” said UC Santa Barbara computer scientist ...
Irvine, Calif., April 16, 2024 — Arctic and boreal latitudes are warming faster than any other region on Earth. In three new studies, Earth system scientists at the University of California, Irvine report how the ecosystems in these regions are changing.
In a study published in Global Change Biology, a team led by Earth system science Ph.D. candidate Jinhyuk Kim from the lab of James Randerson, professor of Earth system science, reveals how wildfires are increasing rates of photosynthesis in Canada and Alaska.
They find that increasing wildfires are wiping out black spruce forests that grow relatively slowly and contribute to the organic layer of the underlying ...
Scientists have found a way to transform metal waste into a highly efficient catalyst to make hydrogen from water, a discovery that could make hydrogen production more sustainable.
A team of researchers from the University of Nottingham's School of Chemistry and Faculty of Engineering have found that the surface of swarf, a byproduct of the metal machining industry, is textured with tiny steps and grooves on a nanoscale level. These textures can anchor atoms of platinum or cobalt, leading to an efficient electrocatalyst ...
For Immediate Release
April 16, 2024
Microplastics, algal blooms, seafood safety are public health concerns addressed by new Oceans and Human Health Centers
NIH and NSF jointly fund new research centers to better understand how ocean-related exposures affect people’s health.
To address plastics and other problems that could affect human health, the NIH and the U.S. National Science Foundation (NSF) are jointly funding four new Centers for Oceans and Human Health and renewing two centers as part of a marine-related health research program. Each Center will focus on a different aspect ...
Almost one-fifth of the global land surface is classified as highly susceptible to rainfall-triggered landslides. According to the World Health Organization, landslides are more widespread than any other geological hazard to occur worldwide and are increasing because of climate change.
Alba Yerro-Colom, assistant professor in the Charles E. Via, Jr. Department of Civil and Environmental Engineering, is motivated to advance the understanding of these natural occurrences while considering how vegetation and changes in rainfall patterns could better predict their potential damage. She ...
Researchers from the University of Michigan Health Rogel Cancer Center have created a urine-based test that detects pieces of DNA fragments released by head and neck tumors. The test could potentially facilitate early detection of this cancer type, which currently does not have a reliable screening method.
Human papillomavirus (HPV) is widely recognized for causing cervical cancer, but is increasingly found to cause cancers in the mouth, throat and other head and neck regions.
Early detection is critical because detecting a cancer at ...
TAMPA, Fla. — Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone. Roughly 90% of men with advanced prostate cancer will develop bone metastases. The disease significantly impacts patients, causing extreme bone pain.
The CAR T-cell therapy, developed in the lab of Moffitt immunologist Daniel Abate-Daga, PhD, utilizes gamma delta T cells to target a tumor biomarker highly expressed in bone metastatic prostate cancer called prostate stem cell antigen. ...
